Idogen publishes interim report for 1 January – 30 June 2021
Idogen AB's interim report for January to June 2021 is available on the company's website https://idogen.com/en/investors/financial-reports/
Second quarter (April-June 2021)
• Other operating income amounted to KSEK 1,731 (2,782)
• Operating loss was KSEK -9,514 (-7,292)
• Loss for the period totaled KSEK -9,604 (-7,976)
• Cash flow from operating activities was KSEK -6,135 (-9,003)
• Loss per share before dilution was SEK -0.53 (-0.87) Loss per share after dilution was SEK -0.53 (-0.87)
Period (January-June 2021)
• Other operating income amounted to KSEK 3,409 (4,195)
• Operating loss was KSEK -20,164 (- 13,925)
• Loss for the period totaled KSEK -20,135 (-14,197)
• Cash flow from operating activities was KSEK -16,087 (-10,788)
• Loss per share before dilution was SEK -1.10 (-2.03). Loss per share after dilution was SEK -1.10 (-2.03)
Significant events in the second quarter
• Preparations for the application to start clinical trials made good progress.
• Documentation and qualification of the production process by Idogen’s partner, the Radboud University Medical Center, continued.
• The COVID-19 pandemic affected work at the Radboud University Medical Center.
Significant events during the period
• Idogen appointed highly reputable scientific advisors in transplantation.
• A Corporate Governance section was added to the Annual Report, and Idogen is now compliant with the Nasdaq listing requirements.
• An additional payment of MSEK 3 was received from the EU’s Horizon 2020 program
Significant events after the end of the period
• The European Patent Office (EPO) announced that a European patent will be granted to protect the company’s tolerogenic cell therapy.
• No other significant events occurred after the end of the period that affected the results or financial position.
For further information, please contact:
Anders Karlsson, CEO, Idogen AB
Phone: +46 70 918 00 10
Email: anders.karlsson@idogen.com
The information was submitted for publication, through the agency of the contact persons set out above, on August 24, 2021 08:50 CET.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care.
Tags: